MediWound Nasdaq: MDWD www.mediwound.com

DEVELOPING BREAKTHROUGH NON-SURGICAL THERAPIES; IMPROVING PATIENT LIVES

- **Validated platform technology: NexoBrid® a commercial product for severe burns; EscharEx® a promising late-stage product for hard to heal wounds; MW005 a clinical-stage program for BCC**
- **Strategic collaborations with Vericel, BARDA and DoD (U.S), Kaken (Japan)**
- **Strong balance sheet, additional $7.5m milestone payment upon BLA approval of NexoBrid® and commercial sales to support clinical development**

EscharEx®: The Game Changer

Next generation enzymatic debridement solution for chronic and hard-to-heal wounds

Significant unmet medical need for topical, rapid and effective debridement agent in outpatient settings

In controlled studies, significantly higher incidence of complete debridement using EscharEx®
(9 days vs. 59 days for patients treated with SOC)

Achieved complete debridement with avg 3.6 topical applications compared to 12.8 with SOC

Demonstrated safe, effective and rapid debridement in VLUs and DFUs; reduced wound size, reduction in biofilm and bacterial burden

Sets a new bar for efficacy; a billion-dollar market opportunity - anticipated to draw market share from all other debridement modalities

Phase III study design discussions with the FDA

Solid balance sheet to support EscharEx® clinical development program

$17.6 million in cash as of Q3/2022 with an additional $17.2 million raised in October 2022

YTD (1-9/22) NexoBrid® generated $14.9 million in revenues; NexoBrid® is cash flow positive

Significant increase in revenues expected in 2023

NexoBrid®: Profitable & Validated

Topical bioactive therapy for burn care; PDUFA target date of January 1, 2023

Clear unmet need for early, effective and selective non-surgical debridement for deep partial and full thickness burns

Clinically and commercially validated

US Strategic alliances: Vericel, BARDA and DoD

Approved in 41 countries; more than 11k patients treated successfully WW

Anticipated EU (EMA) pediatric label extension approval in Q1/2023

MW005: Next Potential

Topical biological drug for the treatment of basal cell carcinoma (BCC)

Unmet medical need for a safe non-surgical treatment that achieves high rates of clinical and histological clearance

Initial Phase I/II study data proves MW005 safe and well-tolerated, with majority of the patients achieving complete histological clearance of target lesions in 5-7 applications

Large market opportunity; 4.3 million diagnosed each year in the U.S

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. These forward-looking statements are based on management’s expectations as of the date hereof and assumptions which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. The use of words such as “intend” and “expect,” among others, generally identify forward-looking statements. However, these words are not the exclusive means of identifying such statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and may include statements relating to the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates. Actual results and the timing and outcome of events may differ materially from those expressed or implied in the forward-looking statements for a variety of reasons, including those detailed in MediWound’s annual report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 17, 2022, Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. Except as required by law, we undertake no obligation to update any forward-looking or other statements in this release, whether as a result of new information, future events or otherwise.

Certain data in this page, was obtained from various external sources, and neither the Company nor its affiliates, advisors or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisors or representatives makes any representations as to the accuracy or completeness of that data or to update such data after the date of this presentation.